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Abstract
Background: The pathogenesis of uterine leiomyomas, the most common benign tumor in women, remains unclear. Since
acquired factors such as obesity, hypertension and early menarche place women at greater risk for uterine leiomyomas,
uterine leiomyomas may be associated with epigenetic abnormalities that are caused by unfavorable environmental
exposures.
Principal Findings: Profiles of genome-wide DNA methylation and mRNA expression were investigated in leiomyomas and
in myometrium with and without leiomyomas. Profiles of DNA methylation and mRNA expression in the myometrium with
and without leiomyomas were quite similar while those in leiomyomas were distinct. We identified 120 genes whose DNA
methylation and mRNA expression patterns differed between leiomyomas and the adjacent myometrium. The biological
relevance of the aberrantly methylated and expressed genes was cancer process, including IRS1 that is related to
transformation, and collagen-related genes such as COL4A1, COL4A2 and COL6A3. We also detected 22 target genes of
estrogen receptor (ER) alpha, including apoptosis-related genes, that have aberrant DNA methylation in the promoter,
suggesting that the aberrant epigenetic regulation of ER alpha-target genes contributes to the aberrant response to
estrogen.
Conclusions: Aberrant DNA methylation and its related transcriptional aberration were associated with cancer processes,
which may represent a critical initial mechanism that triggers transformation of a single tumor stem cell that will eventually
develop into a monoclonal leiomyoma tumor. The aberrant epigenetic regulation of ER alpha-target genes also may
contribute to the aberrant response to estrogen, which is involved in the development of uterine leiomyomas after
menarche.
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Introduction
Uterine leiomyomas are the most common uterine tumors in
reproductive-age women with a prevalence of about 25% [1].
Uterine leiomyomas frequently cause serious gynecological prob-
lems such as pelvic pain, menorrhagia, dysmenorrhea, infertility
and recurrent pregnancy loss [1,2]. In addition, uterine leiomy-
omas are the most common indication for hysterectomy. Risk
factors for uterine leiomyomas include African descent, high body
mass index, meat consumption, early menarche, hypertension and
a history of pelvic inflammatory disease. On the other hand,
factors that lower the risk include use of hormonal contraception,
smoking, giving birth and consumption of green vegetables [3,4,5].
These findings suggest that both genetic and environmental factors
are involved in the development of uterine leiomyomas. In
addition, uterine leiomyomas often show multifocal tumorigenesis
with various sizes from the corresponding myometrium. These
findings suggest that smooth muscle cells of normal myometrium
in the uterus with leiomyomas already acquire the potential in
molecular levels to develop into leiomyomas in future.
DNA methylation is one of the well characterized epigenetic
marks and plays a crucial role in the regulation of gene expression.
DNA methylation is specific to each cell type and has been used to
characterize abnormal cells [6,7,8]. Maintaining the specific DNA
methylation profile of the cell is necessary for cellular integrity, and
alterations in DNA methylation may have serious health
consequences. Environmental factors can be shown to affect
DNA methylation [9,10]. We previously demonstrated that
uterine leiomyomas have an aberrant DNA methylation profile
using genome-wide DNA methylation analysis methods [11,12].
Navarro et al. also analyzed the DNA methylation patterns in
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uterine leiomyomas using genome-wide analysis method in
African American women [13]. They found several aberrantly
methylated and concomitantly expressed genes in leiomyomas,
and suggested that DNA methylation plays a key role in the
pathogenesis of uterine leiomyomas by altering the normal
myometrial mRNA expression profile. The study by Navarro
et al. examined one or two CpG sites in the promoter region in
each gene. Recently, a new type of genome-wide DNA
methylation analysis has been developed, which covers about 16
CpG sites from the promoter to the gene body region. Therefore,
the new analysis will provide more detailed information on
genome-wide DNA methylation profiles in uterine leiomyomas.
Although uterine leiomyomas develop only after menarche and
their growth depends on estrogen, the mechanism is not fully
clarified. The biological effect of estrogen is mediated by estrogen
receptor (ER), which is a transcription factor [1]. DNA
methylation of the gene promoter region directly affects the
response to transcription factors [14]. Thus, aberrant DNA
methylation of the promoter regions of genes targeted by ER
alpha directly may affect the response to estrogen. Recently,
exposure to environmental estrogen during reproductive tract
development has been shown to cause genes targeted by ER alpha
to become hyper-responsive to estrogen in the adult myometrium
[15]. These findings raise the possibility that aberrant DNA
methylation of the promoter of ER alpha-target genes may cause
the aberrant responses to estrogen exposure in uterine leiomyo-
mas, which may be involved in the development of uterine
leiomyomas after menarche.
We previously reported that aberrant DNA hypomethylation is
enriched on the X chromosome in uterine leiomyomas compared
with the adjacent normal myometrium [12]. Interestingly, the X
chromosome was found to have more hypomethylated genes than
other chromosomes [12]. It has been reported that breast cancers,
ovarian cancers, and cervical cancers have aberrant DNA
hypomethylation on the X chromosome such as loss of inactive
X chromosome or aberrant replication of active X chromosome
[16,17]. Therefore, an analysis of the genotype of the X
chromosome might provide clues to the cause of uterine
leiomyomas.
The main objective of this study is to determine whether DNA
methylation patterns are associated with the pathogenesis and
development of uterine leiomyomas. To this end, we 1) compared
the DNA methylation profiles and mRNA expression profiles
among uterine leiomyomas and myometrium with or without
leiomyomas using an advanced genome-wide DNA methylation
analysis method, 2) attempted to identify a subset of genes whose
differential DNA methylation in the promoter is correlated with
differential mRNA expression, 3) identified ER alpha-target genes
that have aberrant DNA methylation in the promoter, and 4)
examined the genotype of the X chromosome and the chromo-




This study was reviewed and approved by the Institutional
Review Board of Yamaguchi University Graduate School of
Medicine. Written informed consent was obtained from the
participants before the collection of any samples, and the
specimens were irreversibly de-identified. All experiments han-
dling human tissues were performed in accordance with Tenets of
the Declaration of Helsinki.
Tissue Preparations
Paired specimens of leiomyoma and adjacent normal myome-
trium were obtained from 10 Japanese women who had a single
leiomyoma nodule to limit biological heterogeneity (Table 1). The
women underwent hysterectomy, and their ages were 44.1+/24.5
years old (mean +/2 SD). The size of leiomyoma ranged from 40
to 160 mm (mean +/2 SD; 85.5+/234.0 mm). All patients
showed intramural leiomyoma. As control myometrium tissues, we
obtained normal myometrium tissue from 3 women who
underwent hysterectomy under the diagnosis of early stage of
cervical cancer (Control 1, Control and Control 3 in Table 1). The
ages of control women were 38.3+/25.0 years old (mean +/2
SD), and did not significantly differ from women with uterine
leiomyomas. None of the women had received previous treatment
with sex steroid hormones or gonadotropin releasing hormone
analogs. Specimens were dissected immediately from the full
thickness uterine wall without the endometrium and serosa after
removal of the uterus, immersed in liquid nitrogen and stored at -
80uC until DNA/RNA extraction. Leiomyomas (L1, L2 and L3)
and adjacent myometrium (M1, M2 and M3) obtained from 3
cases (Case 1, Case 2 and Case 3 in Table 1) were examined by
following genome-wide DNA methylation analysis and mRNA
expression analysis. The myometrium from 3 control women were
also examined (C1, C2, and C3). The other 7 paired samples of
leiomyoma and adjacent myometrium were used in bisulfite
restriction mapping and RT-PCR.
Illumina Infinium HumanMethylation450 BeadChip Assay
Genomic DNA was isolated from 20 mg frozen tissues using the
Qiagen Genomic DNA (Qiagen, Valencia, CA, USA). The DNA
methylation analysis was performed using the Illumina infinium
assay with the HumanMethylation450 BeadChip (Illumina, San
Diego, CA, USA), which interrogates a total of 482,421 CpG sites
spread across the distal promoter regions of transcription start sites
to 39-UTR of consensus coding sequences. Methylated and
unmethylated signals were used to compute beta values, which
are quantitative scores of the DNA methylation levels, ranging
Table 1. Patients with uterine leiomyomas and characteristics
of their leiomyomas.
Age (y.o.) Menstrual phase Type Diameter (mm)
Control 1 43 Follicular –
Control 2 33 Follicular –
Control 3 39 Luteal –
Case 1 49 Luteal intramural 160
Case 2 49 Follicular intramural 90
Case 3 40 Luteal intramural 80
Case 4 43 Follicular intramural 90
Case 5 39 Follicular intramural 70
Case 6 40 Follicular intramural 85
Case 7 38 Luteal intramural 120
Case 8 48 Follicular intramural 40
Case 9 47 Follicular intramural 60
Case 10 48 Luteal intramural 60
Controls 1–3 and Cases 1–3 were used for analysis with Illumina Infinium
HumanMethylation450 BeadChip and Human Gene 1.0 ST array. Cases 1–10
were used for validation of the genes with differential DNA methylation and
mRNA expression.
doi:10.1371/journal.pone.0066632.t001
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from ‘‘0,’’, thus indicating completely unmethylated, to ‘‘1,’’
indicating completely methylated. The BeadChip was scanned on
a BeadArray Reader (Illumina) according to the manufacturer’s
instructions. CpG sites with ‘‘detection p values’’.0.05 (computed
from the background based on negative controls) and CpG sites on
Y chromosome were eliminated from further analysis, leaving
482,005 CpGs valid for use with the nine samples tested. To
perform hierarchical clustering analysis and principal component
analysis, we extracted the CpG sites in which the difference of
maximum beta value and minimum beta value in 9 tissues is
greater than 0.3. To identify the CpGs that showed methylation
changes between leiomyoma and adjacent myometrium, the
difference of beta value of CpGs were calculated in each case.
Then, CpGs expressing greater than 0.3 were extracted. The
microarray data of DNA methylation is available at the Gene
Expression Omnibus Web site (http://www.ncbi.nlm.nih.gov/
geo/) under accession No. GSE45187.
Transcriptome Analysis
Gene expression was analyzed using a GeneChipH Human
Gene 1.0ST Array (Affymetrix, Santa Clara, CA, USA) containing
764,885 probes supporting 28,869 genes. Target cDNA was
prepared from 200 ng of total RNA with the AmbionH WT
Expression kit (Ambion, Austin, TX, USA) and the AffymetrixH
GeneChip WT Terminal Labeling kit (Affymetrix). Hybridization
to the microarrays, washing, staining and scanning were
performed using the GeneChipH system (Affymetrix) composed
of the Scanner 3000 7G Workstation Fluidics 450 and the
Hybridization Oven 645. The scanned image data were processed
using a Gene Expression Analysis with the PartekH Genomics
Suite 6.5 software program (Partech, Munster, Germany). To
perform hierarchical clustering analysis and principal component
analysis, we extracted the gene in which the ratio of maximum
value to minimum value in 9 tissues is greater than 1.5-fold. To
identify the genes that show the difference in mRNA expression
between leiomyoma and adjacent myometrium, a fold-change
greater than 1.5-fold or lesser than 0.67-fold was recognized as a
significant difference. The microarray data of mRNA expression is
available at the Gene Expression Omnibus Web site (http://www.
ncbi.nlm.nih.gov/geo/) under accession No. GSE45188.
Bisulfite Restriction Mapping
Bisulfite reactions were performed as previously reported [18].
The bisulfite-converted DNA was amplified by PCR using the
following sets of primers: IRS1 F: 59-TGTTTTATTT-
TAAATTTTTAGTGGAGAGTAG-39, R: 59-AATATCCCC-
CACCCAAACTATC-39; COL4A1 F: 59-GGAGGGAGGTA-
GAGGATTTATGT-39, R: 59-AAAAACTCCTAAATAAATC-
TAAAAAAAACT-39; GSTM5 F: 59-GGGAGGGGGTTTATT-
GATTTTAGTT-39, R: 59-ACCAATCCTACAACTACTCCA-
CACATC-39. The thermocycling program was an initial cycle of
94uC for 10 min, then 43 cycles of 94uC for 30 sec, 59uC for
30 sec and 72uC for 1 min and finally 10 min of final extension at
72uC. For restriction mapping, 1/2 each of the PCR products was
treated with or without restriction enzyme, and the resulting DNA
fragments were assessed by agarose gel electrophoresis.
Real-time Quantitative RT-PCR
Total RNAs were isolated from tissues using TRIzol reagent
(Invitrogen, Carlsbad, CA, USA) and reverse-transcribed using a
QuantiTect Reverse Transcription Kit (Qiagen) according to the
manufacturer’s protocol. The synthesized DNA was subjected to
PCR reactions using the following sets of primers: IRS1 F: 59-
CAAGACCATCAGCTTCGTGA -39, R: 59- AGAGTCATC-
CACCTGCATCC -39; COL4A1 F: 59- TGGTGACAAAGGA-
CAAGCAG -39, R: 59- GGTTCACCCTTTGGACCTG -39;
GSTM5 F: 59- AATGCCATCCTGCGCTAC -39, R: 59-
TTCTCCAAAATGTCCACACG -39. All PCRs were performed
using SYBR Premix Ex Taq (TAKARA) and a LightCycler
(Roche Applied Science, Basel, Switzerland). A primer set for
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as
an internal control. All samples were run in duplicate. Melting
curves of the products were obtained after cycling by a stepwise
increase of temperature from 55 to 95uC. At the end of 40 cycles,
reaction products were separated electrophoretically on an agarose
gel and stained with ethidium bromide for visual conformation of
the PCR products.
X chromosome Genotyping
The analysis was done using a panel of primers specific for the
following X-linked short tandem repeats markers, obtained from
Genome Database (http://www.gdb.org/) and National Center
for Biotechnology Information (http://www.ncbi.nlm.nih.gov/
genomes/static/euk_g.html): DXS7132, DXS6789, DXS8377
and DXS6807 spanning p and q arms. After PCR using one
fluorescent-labeled primer, the products were separated electro-
phoretically on the Fluorescent Capillary System ABI PRISM 310
and analyzed with GeneScan software (Applied Biosystems). The
allelic status in each case was examined by comparing the allelic
statuses of leiomyoma and adjacent myometrium.
Bioinformatics
MultiExperiment Viewer (MeV in the TM4 microarray
Software Suite; http://www.tm4org/mevhtml) was used for
principal component analysis (PCA) [19]. The analysis for ER
alpha-target genes analysis was performed using the MAPPER
database (http://mapper.chip.org/) [20]. Chromosome distribu-
tion analysis was performed using DAVID 6.7 (http://david.abcc.
ncifcrf.gov/home.jsp) [21]. Integrative Genomics Viewer (http://
www.broadinstitute.org/igv/) was used for chromosomal distribu-
tion map generation [22]. QUMA (http://quma.cdb.riken.jp/)
was used to analyze the bisulfite sequencing data [23].
Results
Analysis of DNA Methylation Profiles of Leiomyomas and
Myometrium with and without Leiomyomas
To compare the genome-wide DNA methylation patterns
among leiomyomas (L1, L2, and L3), the corresponding myome-
trium with leiomyomas (M1, M2, and M3), and the myometrium
without leiomyomas (C1, C2, and C3), the hierarchical clustering
was analyzed according to the DNA methylation status. Myome-
trium without leiomyomas (C1, C2, and C3) and myometrium
with leiomyomas (M1, M2, and M3) showed a similar DNA
methylation profiles, and these 6 tissues were classified into the
same cluster group (Figure 1A). On the other hand, leiomyomas
(L1, L2, and L3) were clustered separately from myometrium with
or without leiomyomas (Figure 1A). The DNA methylation profiles
of these 9 tissues were further compared with a principal
component analysis. In Figure 1B, the component-1 and
component-2 axes clearly distinguished leiomyomas (L1, L2, and
L3) from myometrium with (M1, M2, and M3) or without (C1,
C2, and C3) leiomyomas, while myometrium with leiomyomas
(M1, M2, and M3) was very close to myometrium without
leiomyomas (C1, C2, and C3). These results indicate that
myometrium with and without leiomyomas have quite similar
DNA methylation profiles whereas leiomyomas are clearly
Genome-Wide DNA Methylation Analysis in Leiomyomas
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distinguished from the myometrium in terms of DNA methylation
profiles.
We also analyzed the hierarchical clustering and principal
components of the mRNA expression profiles. In the hierarchical
clustering analysis, myometrium with and without leiomyomas
were classified into the same cluster group, while leiomyomas were
clearly separated from myometrium with or without leiomyomas
(Figure 1C). In the principal component analysis, the component-1
axis clearly distinguished leiomyomas (L1, L2, and L3) from
myometrium with (M1, M2, and M3) or without (C1, C2, and C3)
leiomyomas, whereas myometrium with leiomyomas (M1, M2,
and M3) and myometrium without leiomyomas (C1, C2, and C3)
were not separated into the same group by the component-2 axis
(Figure 1D). The data in Figures 1A and 1B suggest that profiling
by DNA methylation is more useful than profiling by mRNA
expression in defining cell identity.
Analysis of DNA Methylation and mRNA Expression in
Leiomyoma and Matched Adjacent Myometrium
We first compared the DNA methylation profiles between
leiomyomas and adjacent myometrium in each of the three cases
examined in this study. Case1, Case2 and Case3 had 2,386, 1,327
and 3,078 genes, respectively, that were less methylated in the
leiomyomas than in the myometrium (Figure 2A, hypomethylated
genes). Of these hypomethylated genes, 478 genes were shared by
the three cases. Case1, Case2 and Case3 had 2,390, 1,702 and
3,567 genes, respectively, that were more methylated in the
leiomyomas than in the myometrium (Figure 2A, hypermethylated
genes). Of these hypermethylated genes, 1,014 genes were shared
by the three cases.
Messenger RNA expression profiles were also analyzed among
the three cases. Case1, Case2 and Case3 had 1,139, 1,000 and
1,401 genes, respectively, that were upregulated in the leiomyomas
compared with the myometrium (Figure 2B, upregulated genes).
Of these upregulated genes, 349 genes were shared by the three
cases. Case1, Case2 and Case3 had 2,173, 1,058 and 1,197 genes,
respectively, that were downregulated in the leiomyomas com-
pared with the myometrium (Figure 2B, downregulated genes). Of
these downregulated genes, 576 genes were shared by the three
cases.
We then selected 120 genes that had both aberrant DNA
methylation and aberrant mRNA expression. Of these genes, 24
genes were less methylated and transcriptionally upregulated in
the leiomyomas compared with the myometrium, and 65 genes
were more methylated and transcriptionally downregulated in the
leiomyomas compared with the myometrium. According to the
Ingenuity Pathways Analysis (IPA) [24], in the 24 hypomethylated
and upregulated genes, the most specific pathway was ‘‘cancer
process’’ in the section of diseases and disorders (Figure 2D). The
genes included in the category ‘‘cancer process’’ are shown in
Table 2. Collagen-related genes such as COL4A1 and COL4A2
have been previously reported to be upregulated in leiomyomas
[25,26,27]. In the 65 hypermethylated and downregulated genes,
the most specific pathway was also ‘‘cancer process’’ (Figure 2E).
The genes included in the category ‘‘cancer process’’ are shown in
Table 2. Glutathione S-transferase mu 5 (GSTM5) is a member of
glutathione S-transferase family and protects cells as an anti-
oxidant enzyme against reactive oxygen species. GSTM5 is also
known to be involved in cancer development [28].
Validation of the Genes with Differential DNA
Methylation and mRNA Expression
Among the hypomethylated and upregulated genes, we focused
on insulin receptor substrate 1 (IRS1) and COL4A1 which have
aberrant DNA hypomethylation in the gene body closed to the
promoter region. IRS1 is initially characterized as a cytosolic
adaptor protein involved in insulin receptor (INSR) and insulin-
like growth factor 1 receptor (IGF1R) signaling. More recently, it
has been shown to be involved in proliferation and transformation
of cancer cells [29,30]. First, we examined the DNA methylation
status of the IRS1 and COL4A1 using combined bisulfite
restriction analysis in Case1, Case2, Case3 and additional 7
paired samples of leiomyoma and matched myometrium. As
shown in Figure 3A, the methylation levels of the IRS1 were lower
than those in myometrium in all the 10 samples. In addition,
mRNA levels of IRS1 in leiomyomas were higher than those in
myometrium in all the 10 samples (Figure 3D). In COL4A1, the
methylation levels in leiomyomas were lower than those in
myometrium in all samples except Case7 (Figure 3B), and mRNA
levels in leiomyomas were higher than those in myometrium in all
samples except Case7 (Figure 3E).
To examine the possibility that IRS1 mRNA expression is
under the regulation of DNA methylation, immortalized human
uterine smooth muscle cells (16106 cells/25 cm2 tissue culture
flask) were treated by an inhibitor of DNA methylation (5-aza-dC,
1 uM) for 96 h. IRS1 mRNA levels were significantly (p,0.05)
increased by 5-aza-dC, suggesting that DNA methylation is
involved in the regulation of IRS1 mRNA expression (data not
shown). The treatment with 5-aza-dC caused no significant
changes in cell morphology and cell proliferation.
Among the hypermethylated and downregulated genes, we
focused on GSTM5 which has aberrant DNA hypomethylation in
the promoter region. As shown in Figure 3C and 3F, the
methylation levels of the GSTM5 promoter in leiomyomas were
higher than those in myometrium while mRNA levels of GSTM5
in leiomyomas were remarkably lower than those in myometrium
in all the 10 samples.
ER Alpha- target Genes with Aberrant DNA Methylation
and mRNA Expression
In the aberrantly methylated and expressed 120 genes, 22 genes
which have the consensus sequences of ER response element
(ERE) in the promoter region (from 21,000 bp to the transcrip-
tion start site) were extracted using the MAPPER database [20]
(Table 3). In addition to COL4A1, COL6A3 and GSTM5,
Figure 1. DNA methylation profiling and mRNA expression profiling of leiomyomas and myometrium with and without
leiomyomas. DNA methylation profiles and mRNA expression profiles of leiomyomas (L1, L2 and L3), myometrium with leiomyomas (M1, M2 and
M3) and myometrium without leiomyomas (C1, C2 and C3) were compared using hierarchical clustering analyses and principal component analyses.
A: Hierarchical clustering analyses according to DNA methylation profiles. The Heat map in hierarchical clustering analysis indicates DNA methylation
levels from unmethylated (blue) to completely methylated (yellow). Distances of DNA methylation pattern (Euclidean Distances) were calculated by
MultiExperiment Viewer. B: Principal component analyses according to DNA methylation profiles. Vertical axis and horizontal axis show principal
component numbers, respectively. The principal component analyses were performed using MultiExperiment Viewer. C: Hierarchical clustering
analyses according to mRNA expression profiles. The Heat map in hierarchical clustering analysis indicates mRNA expression levels from low (blue) to
high (yellow). Distances of mRNA expression pattern (Euclidean Distances) were shown on the left side. D: Principal component analyses according to
mRNA expression profiles. Vertical axis and horizontal axis show principal component numbers, respectively.
doi:10.1371/journal.pone.0066632.g001
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DAPK1 (death-associated protein kinase 1) and NUAK1 (novel
kinase family 1), which were hypermethylated and transcription-
ally downregulated, were included. DAPK1, which is a tumor
suppressor gene, has been shown to be associated with apoptosis,
and the downregulation and DNA hypermethylation were
reported in several tumors [31,32,33,34]. NUAK1 is known to
possess tumor suppressive properties through the control of
cellular senescence [35,36].
Analysis of X chromosome Genotype
Recent reports have shown that in females, some cancer cells
lose an inactive X chromosome and replicate an active X
chromosome. It is called ‘‘loss-of-inactive X chromosome and
gain-of-active X chromosome’’ [16,17]. The cancer cells affected
by this event have two active X chromosomes, resulting in the
DNA hypomethylation status in X chromosome. Therefore, we
decided to investigate whether uterine leiomyomas suffer this event
and result in the hypomethylation status of X chromosome. Since
the cells affected by this event should have two genetically same X
chromosomes, we investigated the heterozygosity of X chromo-
somes in leiomyomas using following X-linked short tandem
repeats markers: DXS7132, DXS6789, DXS8377 and DXS6807
spanning p and q arms. The result showed that all three cases
showed heterozygosity in both myometrium and leiomyomas in all
markers (Figure 4), indicating that both the leiomyoma and
myometrium have a normal X chromosome genotype.
Chromosome Distribution of Aberrantly Methylated CpG
Sites
Aberrant hypomethylation and hypermethylation occurred on
all chromosomes in all three cases (Figure 5). Hypermethylated
CpG sites (red) were enriched compared with hypomethylated
CpG sites (green) in the autosomes in all three cases (Figure 5).
On the other hand, X chromosome was preferentially enriched
with hypomethylated CpG sites (green) in all three cases with
remarkably low p values (5.31E-95 in Case 1, 1.34E-55 in Case
2, 1.63E-14 in Case 3), and the distribution of the hypomethy-
lated CpG sites was observed throughout the X chromosome
(Figure 5).
Discussion
We performed a genome-wide DNA methylation analysis in
uterine leiomyomas using a method that interrogates over
450,000 CpG sites of DNA methylation statuses of consensus
coding sequences. Our results suggest that uterine leiomyomas
are associated with genome-wide alterations in DNA methyla-
tion at multiple gene promoter regions.
Does the Adjacent Myometrium with Leiomyoma have
the Potential to Develop into Uterine Leiomyomas?
Uterine leiomyomas often show multifocal tumorigenesis from
the myometrium. We speculated that the adjacent myometrium,
which looks normal, has the potential to develop into leiomyomas,
Figure 2. Aberrantly methylated or expressed genes in Leiomyomas. A: Venn diagrams show the number of aberrantly hypomethylated or
hypermethylated genes in 3 paired samples. B: Venn diagrams show the number of aberrantly upregulated or downregulated genes in 3 paired
samples. C: Integration of DNA methylation and mRNA expression data in uterine leiomyoma and adjacent myometrium. The numbers of genes
which have both aberrant methylation and aberrant mRNA expression are shown. D: Functional analysis of 24 genes that have aberrant
hypomethylation and upregulation of mRNA. The functional categories are shown with the number of included genes and p-values. Functional
analysis was performed using IPA. E: Functional analysis of 65 genes that have aberrant hypermethylation and downregulation of mRNA. The
functional categories are shown with the number of included genes and p-values. Functional analysis was performed using IPA.
doi:10.1371/journal.pone.0066632.g002
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Table 2. Aberrantly methylated and expressed genes contained in "cancer process".
Gene symbol Gene fold change
Hypomethylated and transcriptionally upregulated genes
CACNA1C calcium channel, voltage-dependent, L type, alpha 1C subunit 1.974
COL4A1 collagen, type IV, alpha 1 1.822
COL4A2 collagen, type IV, alpha 2 2.022
COL6A3 collagen, type VI, alpha 3 1.950
CYP1B1 cytochrome P450, family 1, subfamily B, polypeptide 1 1.844
IRS1 insulin receptor substrate 1 2.395
KIAA1199 KIAA1199 8.507
POPDC2 popeye domain containing 2 4.952
PRL prolactin 8.828
RAD51L1(RAD51B) RAD51-like 1 (S. cerevisiae) 3.712
TACR2 tachykinin receptor 2 2.862
UNC5D unc-5 homolog D (C. elegans) 3.851
VCAN versican 2.677
WBSCR17 Williams-Beuren syndrome chromosome region 17 2.177
Hypermethylated and transcriptionally downregulated genes
AIM1 absent in melanoma 1 21.917
ANXA3 annexin A3 24.190
CD74 CD74 molecule, major histocompatibility complex, class I 21.620
CFB complement factor B 22.170
DAPK1 death-associated protein kinase 1 22.007
DPP4 dipeptidyl-peptidase 4 22.825
DUSP6 dual specificity phosphatase 6 22.332
EFEMP1 EGF-containing fibulin-like extracellular matrix protein 29.696
EPAS1 endothelial PAS domain protein 1 22.369
EZR ezrin 22.227
FOXP1 forkhead box P1 20.626
GATA2 GATA binding protein 2 22.460
GSTM5 glutathione S-transferase mu 5 29.998
HTATIP2 HIV-1 Tat interactive protein 2, 30 kDa 23.253
IGF2BP3 insulin-like growth factor 2 mRNA binding protein 3 21.684
KAT2B K(lysine) acetyltransferase 2B 22.715
KDR kinase insert domain receptor 22.565
LDB2 LIM domain binding 2 22.034
LIMA1 LIM domain and actin binding 1 21.759
MEOX2 mesenchyme homeobox 2 21.850
MYEF2 myelin expression factor 2 22.304
NR3C1 nuclear receptor subfamily 3, group C, member 1 22.132
NR4A2 nuclear receptor subfamily 4, group A, member 2 21.931
NR4A3 nuclear receptor subfamily 4, group A, member 3 22.136
NR5A2 nuclear receptor subfamily 5, group A, member 2 22.317
NRN1 neuritin 1 23.641
NTRK2 neurotrophic tyrosine kinase, receptor, type 2 22.175
NUAK1 NUAK family, SNF1-like kinase, 1 22.568
PLCE1 phospholipase C, epsilon 1 24.468
SDPR serum deprivation response 22.895
SORBS2 sorbin and SH3 domain containing 2 22.291
SPTBN1 spectrin, beta, non-erythrocytic 1 21.957
TIAM1 T-cell lymphoma invasion and metastasis 1 21.730
The fold change was calculated as values of leiomyoma relative to adjacent myometrium in each case in the mRNA expression microarray.
doi:10.1371/journal.pone.0066632.t002
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i.e., already has aberrant DNA methylation. In this study, we
selected paired tissue samples of leiomyoma and adjacent
myometrium from women who had a single leiomyoma nodule.
Interestingly, the DNA methylation status of the myometrium
adjacent to the leiomyoma was quite similar to that in the normal
uterine myometrium. This result suggests that adjacent myome-
trium with a leiomyoma nodule does not acquire the potential in
DNA methylation levels to develop into leiomyomas. Another
possibility is that cells with aberrant DNA methylation are present
in the adjacent myometrium, but are too few to detect. In other
words, aberrant DNA methylation may occur only in a limited
number of cells. Recently, Ono et al. reported that side population
cells in the myometrium and leiomyoma tissues act as tissue stem
cells and have the potential to differentiate and proliferate [37,38].
It has also been shown that each leiomyoma nodule shows
monoclonal cell feature [39], indicating that each leiomyoma
nodule is derived from just one affected cell as the origin of the
tumor. Taken together, these findings suggest that tumor stem cells
with aberrant DNA methylation are present in the myometrium
and develop into leiomyoma nodules.
Identification of Genes with Aberrant DNA Methylation
that are Associated with Tumorigenesis of Uterine
Leiomyomas
Of 120 genes that had both aberrant DNA methylation and
aberrant mRNA expression in leiomyomas, 24 genes were less
methylated and transcriptionally upregulated in the leiomyomas
compared with the myometrium, and 65 genes were more
methylated and transcriptionally downregulated in the leiomyo-
mas compared with the myometrium. The biological relevance of
these aberrantly methylated and concomitantly expressed genes
was ‘‘cancer process’’ in the section of diseases and disorders
according to IPA. The genes associated with ‘‘cancer process’’
contained potentially novel or relevant candidate genes for
leiomyoma formation such as IRS1, COL4A1, COL4A2,
COL6A3, and GSTM5.
Gene expression of IRS1 was found to be increased in uterine
leiomyomas in this study. IRS1 has been shown to be involved in
cancer progression and metastasis by mediating proliferative and
anti-apoptotic functions of the INSR and IGF1R signaling
[30,40]. Recently, IRS1 has been found to have a novel function
in addition to its role in intracellular signal transduction.
Interestingly, nuclear presence of IRS1 contributes to malignant
transformation [41]. Overexpression or ectopic expression of IRS1
Figure 3. Analyses of DNA methylation levels and mRNA expression levels of IRS1, COL4A1 and GSTM5. DNA methylation levels and
mRNA expression levels of IRS1, COL4A1 and GSTM5 were examined on 10 paired samples with myometrium (Myomet) and leiomyoma (Leio). DNA
methylation levels of IRS1 (A), COL4A1 (B) and GSTM5 (C) were evaluated by bisulfite restriction mapping, quantified by densitometry, and expressed
as %methylated DNA. The levels of mRNA expression of IRS1 (D), COL4A1 (E) and GSTM5 (F) were quantified by real-time quantitative RT-PCR and
were normalized to GAPDH. The mRNA level in the myometrium of Case1 was expressed as 1.
doi:10.1371/journal.pone.0066632.g003
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causes cell transformation, including development of the ability to
form colonies and tumors [42,43]. In contrast, when IRS1
expression is experimentally decreased, cancer cells lose their
transformed phenotype [44,45,46].
In the present study, the gene expressions of COL4A1,
COL4A2 and COL6A3 were found to be increased in uterine
leiomyomas. Extracellular matrix (ECM) plays an important role
in the pathophysiology of uterine leiomyomas. Collagens are most
predominant components of ECM of uterine leiomyomas [1].
Increased production of collagens contributes to the volume
expansion and fibroid formation [1]. IRS1 is also reported to be
involved in the upregulation of collagen genes, including
COL4A1, COL4A2 and COL6A3, suggesting that IRS1 possibly
contributes to the leiomyoma nodule formation by upregulating
the gene expression of COL4A1, COL4A2, and COL6A3 [47].
On the other hand, gene expression of GSTM5 was decreased
in uterine leiomyomas. GST family has been shown to play a
crucial role in preventing DNA damage [48,49], and overexpres-
sion of GST family inhibits oxidative stress-induced apoptosis and
results in cell proliferation [48,49]. Interestingly, GSTM5, one of
mu-classes of GST family, may have a different function in
tumorigenesis. Peng et al. [34] reported that promoter DNA
hypermethylation and low mRNA expression of GSTM5 was
observed in Barrett’s adenocarcinoma, and suggested that DNA
hypermethylation of GSTM5 is an early event in carcinogenesis
[28]. Aberrant DNA hypermethylation and downregulation of
GSTM5 have also been reported in brain tumors, salivary gland
cancers and leukemia [50,51,52]. However, the detailed role of
GSTM5 in cancer development remains to be explored.
It is interesting to note that uterine leiomyomas develop only
after menarche, indicating that growth of uterine leiomyomas
depends on estrogen. We hypothesize that aberrant DNA
methylation of the promoter regions of genes targeted by ER
alpha causes an abnormal response to estrogen in uterine
leiomyomas. Thus, tumor stem cells of leiomyomas in the
myometrium may have become hyper-responsive or hypo-
responsive to estrogen. In fact, exposure to environmental estrogen
during reproductive tract development caused genes targeted by
ER alpha to become hyper-responsive to estrogen in the adult
myometrium [15]. The present study detected 22 ER alpha-target
genes with both aberrant DNA methylation and aberrant mRNA
expression, including COL4A1, COL6A3, DAPK1, and NUAK1.
For example, if the promoter is aberrantly hypomethylated in ER
alpha-target genes, ER alpha can bind to the promoter, resulting
in a hyper-response to estrogen. In the case of the COL4A1 and
COL6A3 genes, estrogen exposure causes overproduction of
collagens after menarche. On the other hand, if the promoter is
aberrantly hypermethylated in the ER alpha-target genes, ER
alpha cannot bind to the promoter, resulting in a poor response to
estrogen. In the case of DAPK1 and NUAK1, which are
apoptosis-related genes that are induced by estrogen, apoptosis is
not caused by estrogen, resulting in cell proliferation after
menarche. Taken together, these findings suggest that aberrant
responses of ER alpha-target genes to estrogen caused by aberrant
Table 3. Estrogen receptor alpha-target genes with aberrant DNA methylation in the promoter and aberrant mRNA expression.
Gene mRNA expression#
Hypomethylated ERa target genes
COL4A1 collagen, type IV, alpha 1 q
COL6A3 collagen, type VI, alpha 3 q
RPL39 ribosomal protein L39 q
ZMAT3 zinc finger, matrin-type 3 q
OXTR oxytocin receptor Q
Hypermethylated ERa target genes
BCAN brevican q
KIF5C kinesin family member 5C q
NPTX2 neuronal pentraxin II q
TFAP2C transcription factor AP-2 gamma q
SCIN scinderin q
THBS2 thrombospondin 2 q
OCIAD2 OCIA domain containing 2 Q
CRHBP corticotropin releasing hormone binding protein Q
NUAK1 NUAK family, SNF1-like kinase, 1 Q
CCDC68 coiled-coil domain containing 68 Q
NR5A2 nuclear receptor subfamily 5, group A, member 2 Q
ELTD1 EGF, latrophilin and seven transmembrane domain containing 1 Q
FAM162B family with sequence similarity 162, member B Q
IGF2BP3 insulin-like growth factor 2 mRNA binding protein 3 Q
DAPK1 death-associated protein kinase 1 Q
GSTM5 glutathione S-transferase mu 5 Q
EZR ezrin Q
#Microarray mRNA expression statuses of leiomyoma relative to adjacent myometrium are shown.
doi:10.1371/journal.pone.0066632.t003
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DNA methylation in their promoter are involved in the
development of uterine leiomyomas after menarche.
One may have a question whether the genes with aberrant
expression in ‘‘cancer process’’ identified in uterine leiomyomas
are also involved in the development of uterine leiomyosarcomas.
Skubitz et al. previously reported aberrant overexpression of 16
genes in leiomyosarcomas [53], but those genes were different
from the genes with aberrant expression in this study. Also, uterine
leiomyosarcoma development is generally independent on estro-
gen exposure.
It is reported that tumor stem cells of uterine leiomyomas do not
respond to estrogen because of low ER expression [38]. It is
unclear how tumor stem cells of leiomyomas acquire the
responsiveness to estrogen. Interestingly, recent evidence has
shown that IRS1 regulates the transcription of ER alpha-target
genes by forming a complex with ER alpha [54]. The IRS1/ER-
alpha complex translocates into the nucleus and interacts with the
promoter region containing ER-responsive elements, which in
turn influences transcriptional activities via decreasing proteolytic
turnover of ER alpha [54]. IRS1 also enhances ER alpha activities
via the PI-3K/Akt pathway [55,56]. From these findings, we
speculate that tumor stem cells with overexpression of IRS1
respond to estrogen by acquiring ER alpha expression and
stimulating ER alpha activities, resulting in the development of
leiomyomas.
Recently, Navarro et al. reported 10 hypomethylated and
transcriptionally upregulated genes, and 36 hypermethylated and
transcriptionally downregulated genes in uterine leiomyomas
compared with the corresponding myometrium using genome-
wide approach [13]. However, the aberrant genes reported by
Figure 4. X chromosomal microsatellite analysis of leiomyoma and adjacent myometrium. Chromatographs using four tandem repeat
markers (DXS7132, DXS6789, DXS8377 and DXS6807) are indicated. Chromatographs of DNA from leiomyoma (L) and adjacent myometrium (M)
obtained from Case1 (Top), Case2 (Middle) and Case3 (Bottom) are shown. The PCR products of DXS7132, DXS6789, DXS8377 and DXS6807 were
separated electrophoretically on a Fluorescent Capillary System ABI PRISM 310 and analyzed with GeneScan software (Applied Biosystems). The allelic
status in each case was examined by comparing the allelic statuses of the leiomyoma and adjacent myometrium.
doi:10.1371/journal.pone.0066632.g004
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them were not consistent with the genes identified in this study.
There seem to be a number of differences between two studies.
First, the method used for DNA methylation analysis differs. The
genome-wide approach used by Navarro et al. covered a few CpG
sites in the promoter region in each gene (1–2 CpG sites per gene)
while our method can cover much more CpG sites (about 16 CpG
sites per gene) broadly from the promoter to the gene body region.
Second, the gene extraction algorithm is different between the two
studies. We compared the difference in DNA methylation and
mRNA expression in a paired sample in each case, and extracted
the aberrantly methylated and differentially expressed gene, in
which all the three cases showed common aberrations. On the
other hand, Navarro et al. compared the difference in DNA
methylation and mRNA expression between the uterine leiomy-
oma group and the myometrium group with the limma package
which is based on t-statistic, but did not do in a paired sample in
each case [13,24]. Furthermore, we analyzed Japanese women
who had a single leiomyoma nodule while Navarro et al. analyzed
uterine leiomyomas with multiple nodules from African American
women. More importantly, there must be inevitable differences in
DNA methylation among individuals, which may be due to the
difference in various local and environmental factors among
individuals. In fact, we found that the DNA methylation status of
the promoter region of ER alpha gene and GS20656 gene
(differently methylated genomic loci in uterine leiomyomas) varies
in even normal myometrium among individuals [11,18], which
may represent a within-physiological change in a certain cell type
such as smooth muscle cells in myometrium [11,18]. These
differences between the two studies and the individual-related
difference should be taken into consideration with some caution,
Figure 5. The chromosomal distribution of aberrantly methylated CpGs in uterine leiomyomas. The locations of CpGs, in which the
difference of beta value between leiomyoma and adjacent myometrium are greater than 0.3, are shown with green bar (hypomethylated CpG in
leiomyoma) or red bar (hypermethylated CpG in leiomyoma). The chromosomal distribution of aberrantly methylated CpGs was shown in Case1 (A),
Case2 (B) and Case3 (C). Autosomal chromosomal number and sex chromosome are shown on the bottom. D: All chromosomes are aligned side by
side in a row (Top), and X chromosome is shown in magnified scale (Bottom). Green bar (hypomethylated CpG in leiomyoma) and red bar
(hypermethylated CpG in leiomyoma) are shown in the same line.
doi:10.1371/journal.pone.0066632.g005
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and further studies are needed to make a more definitive
conclusion.
X Chromosome Genotyping and Chromosome
Distribution of Aberrant DNA Methylation
In the present study, we used an advanced genome-wide DNA
methylation analysis to confirm that hypomethylated-CpG sites
were remarkably enriched on the X chromosome in uterine
leiomyomas compared with adjacent myometrium. Loss of the
inactive X chromosome and aberrant replication of the active X
chromosome has been shown in several female-related cancer cells
[16,17]. Our analysis of the X chromosome genotype demon-
strated that these events do not occur in uterine leiomyomas. The
mechanism of DNA hypomethylation in the X chromosome in
uterine leiomyomas is likely to be different from that in other
cancer cells [16,17]. We have suggested that X-inactivation
machineries are disturbed in uterine leiomyomas [12]. However,
the detailed mechanism of the enriched DNA hypomethylation in
X chromosome in uterine leiomyomas, and the relationship
between DNA hypomethylation status of X chromosome and the
pathogenesis of uterine leiomyomas remain to be elucidated. In
the course of this study, we identified 11 genes in the X
chromosome of uterine leiomyomas that were hypomethylated
in all three cases (data not shown). We are now examining these
genes to see if they have roles in the pathogenesis of uterine
leiomyomas.
Conclusions
We propose the following hypothesis for pathogenesis of uterine
leiomyomas: tissue stem cells in the myometrium transform to
tumor stem cells by suffering genome-wide aberrant DNA
methylation by unknown factors such as unfavorable environ-
mental exposures. Aberrant DNA methylation and its related
transcriptional aberration in cancer-related genes such as IRS1
may represent a critical initial mechanism that triggers transfor-
mation of a single tissue stem cell to a tumor stem cell, which will
eventually develop into a monoclonal leiomyoma tumor. In
addition, the aberrant DNA methylation of the promoter of ER
alpha-target genes, e.g. COL4A1, COL6A3, DAPK1 and
NUAK1, is responsible for the aberrant response to estrogen.
The tumor stem cells aberrantly respond to estrogen after
menarche, and gradually proliferate and differentiate to form
leiomyoma nodules.
Our results suggest that aberrant DNA methylation contributes
to the pathogenesis of uterine leiomyomas and may lead to the
development of new strategies for treatment.
Author Contributions
Conceived and designed the experiments: RM NS. Performed the
experiments: RM. Analyzed the data: RM SS YY ET AN NS. Contributed
reagents/materials/analysis tools: SS HA IT LL MO HT. Wrote the
paper: RM NS.
References
1. Stewart EA (2001) Uterine fibroids. Lancet 357: 293–298.
2. Bajekal N, Li TC (2000) Fibroids, infertility and pregnancy wastage. Hum
Reprod Update 6: 614–620.
3. Chiaffarino F, Parazzini F, La Vecchia C, Chatenoud L, Di Cintio E, et al.
(1999) Diet and uterine myomas. Obstet Gynecol 94: 395–398.
4. Faerstein E, Szklo M, Rosenshein N (2001) Risk factors for uterine leiomyoma: a
practice-based case-control study. I. African-American heritage, reproductive
history, body size, and smoking. Am J Epidemiol 153: 1–10.
5. Faerstein E, Szklo M, Rosenshein NB (2001) Risk factors for uterine leiomyoma:
a practice-based case-control study. II. Atherogenic risk factors and potential
sources of uterine irritation. Am J Epidemiol 153: 11–19.
6. Shiota K, Yanagimachi R (2002) Epigenetics by DNA methylation for
development of normal and cloned animals. Differentiation 69: 162–166.
7. Lieb JD, Beck S, Bulyk ML, Farnham P, Hattori N, et al. (2006) Applying
whole-genome studies of epigenetic regulation to study human disease.
Cytogenet Genome Res 114: 1–15.
8. Shiota K, Kogo Y, Ohgane J, Imamura T, Urano A, et al. (2002) Epigenetic
marks by DNA methylation specific to stem, germ and somatic cells in mice.
Genes Cells 7: 961–969.
9. Iwatani M, Ikegami K, Kremenska Y, Hattori N, Tanaka S, et al. (2006)
Dimethyl sulfoxide has an impact on epigenetic profile in mouse embryoid body.
Stem Cells 24: 2549–2556.
10. Wu Q, Ohsako S, Ishimura R, Suzuki JS, Tohyama C (2004) Exposure of mouse
preimplantation embryos to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) alters
the methylation status of imprinted genes H19 and Igf2. Biol Reprod 70: 1790–
1797.
11. Yamagata Y, Maekawa R, Asada H, Taketani T, Tamura I, et al. (2009)
Aberrant DNA methylation status in human uterine leiomyoma. Mol Hum
Reprod 15: 259–267.
12. Maekawa R, Yagi S, Ohgane J, Yamagata Y, Asada H, et al. (2011) Disease-
dependent differently methylated regions (D-DMRs) of DNA are enriched on
the X chromosome in uterine leiomyoma. J Reprod Dev 57: 604–612.
13. Navarro A, Yin P, Monsivais D, Lin SM, Du P, et al. (2012) Genome-wide DNA
methylation indicates silencing of tumor suppressor genes in uterine leiomyoma.
PLoS One 7: e33284.
14. Hitchler MJ, Wikainapakul K, Yu L, Powers K, Attatippaholkun W, et al. (2006)
Epigenetic regulation of manganese superoxide dismutase expression in human
breast cancer cells. Epigenetics 1: 163–171.
15. Greathouse KL, Bredfeldt T, Everitt JI, Lin K, Berry T, et al. (2012)
Environmental estrogens differentially engage the histone methyltransferase
EZH2 to increase risk of uterine tumorigenesis. Mol Cancer Res 10: 546–557.
16. Kawakami T, Zhang C, Taniguchi T, Kim CJ, Okada Y, et al. (2004)
Characterization of loss-of-inactive X in Klinefelter syndrome and female-
derived cancer cells. Oncogene 23: 6163–6169.
17. Sirchia SM, Ramoscelli L, Grati FR, Barbera F, Coradini D, et al. (2005) Loss of
the inactive X chromosome and replication of the active X in BRCA1-defective
and wild-type breast cancer cells. Cancer Res 65: 2139–2146.
18. Asada H, Yamagata Y, Taketani T, Matsuoka A, Tamura H, et al. (2008)
Potential link between estrogen receptor-alpha gene hypomethylation and
uterine fibroid formation. Mol Hum Reprod 14: 539–545.
19. Saeed AI, Sharov V, White J, Li J, Liang W, et al. (2003) TM4: a free, open-
source system for microarray data management and analysis. Biotechniques 34:
374–378.
20. Marinescu V, Kohane I, Riva A (2005) The MAPPER database: a multi-
genome catalog of putative transcription factor binding sites. Nucleic Acids Res
33: D91–97.
21. Huang da W, Sherman BT, Tan Q, Kir J, Liu D, et al. (2007) DAVID
Bioinformatics Resources: expanded annotation database and novel algorithms
to better extract biology from large gene lists. Nucleic Acids Res 35: W169–175.
22. Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, et al.
(2011) Integrative genomics viewer. Nat Biotechnol 29: 24–26.
23. Kumaki Y, Oda M, Okano M (2008) QUMA: quantification tool for
methylation analysis. Nucleic Acids Res 36: W170–175.
24. Feng G, Du P, Krett NL, Tessel M, Rosen S, et al. (2010) A collection of
bioconductor methods to visualize gene-list annotations. BMC Res Notes 3: 10.
25. Vanharanta S, Wortham NC, Laiho P, Sjoberg J, Aittomaki K, et al. (2005) 7q
deletion mapping and expression profiling in uterine fibroids. Oncogene 24:
6545–6554.
26. Gilden M, Malik M, Britten J, Delgado T, Levy G, et al. (2012) Leiomyoma
fibrosis inhibited by liarozole, a retinoic acid metabolic blocking agent. Fertil
Steril.
27. Weston G, Trajstman AC, Gargett CE, Manuelpillai U, Vollenhoven BJ, et al.
(2003) Fibroids display an anti-angiogenic gene expression profile when
compared with adjacent myometrium. Mol Hum Reprod 9: 541–549.
28. Peng DF, Razvi M, Chen H, Washington K, Roessner A, et al. (2009) DNA
hypermethylation regulates the expression of members of the Mu-class
glutathione S-transferases and glutathione peroxidases in Barrett’s adenocarci-
noma. Gut 58: 5–15.
29. Morelli C, Garofalo C, Sisci D, del Rincon S, Cascio S, et al. (2004) Nuclear
insulin receptor substrate 1 interacts with estrogen receptor alpha at ERE
promoters. Oncogene 23: 7517–7526.
30. Esposito DL, Aru F, Lattanzio R, Morgano A, Abbondanza M, et al. (2012) The
insulin receptor substrate 1 (IRS1) in intestinal epithelial differentiation and in
colorectal cancer. PLoS One 7: e36190.
31. Martoriati A, Doumont G, Alcalay M, Bellefroid E, Pelicci PG, et al. (2005)
dapk1, encoding an activator of a p19ARF-p53-mediated apoptotic checkpoint,
is a transcription target of p53. Oncogene 24: 1461–1466.
32. Raval A, Tanner SM, Byrd JC, Angerman EB, Perko JD, et al. (2007)
Downregulation of death-associated protein kinase 1 (DAPK1) in chronic
lymphocytic leukemia. Cell 129: 879–890.
Genome-Wide DNA Methylation Analysis in Leiomyomas
PLOS ONE | www.plosone.org 12 June 2013 | Volume 8 | Issue 6 | e66632
33. Claus R, Hackanson B, Poetsch AR, Zucknick M, Sonnet M, et al. (2012)
Quantitative analyses of DAPK1 methylation in AML and MDS. Int J Cancer
131: E138–142.
34. Missaoui N, Hmissa S, Trabelsi A, Traore C, Mokni M, et al. (2011) Promoter
hypermethylation of CDH13, DAPK1 and TWIST1 genes in precancerous and
cancerous lesions of the uterine cervix. Pathol Res Pract 207: 37–42.
35. Bernard D, Augert A (2010) NUAK1 links genomic instability and senescence.
Aging (Albany NY) 2: 317–319.
36. Hou X, Liu JE, Liu W, Liu CY, Liu ZY, et al. (2011) A new role of NUAK1:
directly phosphorylating p53 and regulating cell proliferation. Oncogene 30:
2933–2942.
37. Ono M, Maruyama T, Masuda H, Kajitani T, Nagashima T, et al. (2007) Side
population in human uterine myometrium displays phenotypic and functional
characteristics of myometrial stem cells. Proc Natl Acad Sci U S A 104: 18700–
18705.
38. Ono M, Qiang W, Serna VA, Yin P, Coon JSt, et al. (2012) Role of stem cells in
human uterine leiomyoma growth. PLoS One 7: e36935.
39. Zhang P, Zhang C, Hao J, Sung CJ, Quddus MR, et al. (2006) Use of X-
chromosome inactivation pattern to determine the clonal origins of uterine
leiomyoma and leiomyosarcoma. Hum Pathol 37: 1350–1356.
40. White MF (2002) IRS proteins and the common path to diabetes. Am J Physiol
Endocrinol Metab 283: E413–422.
41. Reiss K, Del Valle L, Lassak A, Trojanek J (2012) Nuclear IRS-1 and cancer.
J Cell Physiol 227: 2992–3000.
42. DeAngelis T, Chen J, Wu A, Prisco M, Baserga R (2006) Transformation by the
simian virus 40 T antigen is regulated by IGF-I receptor and IRS-1 signaling.
Oncogene 25: 32–42.
43. Valentinis B, Romano G, Peruzzi F, Morrione A, Prisco M, et al. (1999) Growth
and differentiation signals by the insulin-like growth factor 1 receptor in
hemopoietic cells are mediated through different pathways. J Biol Chem 274:
12423–12430.
44. Cesarone G, Garofalo C, Abrams MT, Igoucheva O, Alexeev V, et al. (2006)
RNAi-mediated silencing of insulin receptor substrate 1 (IRS-1) enhances
tamoxifen-induced cell death in MCF-7 breast cancer cells. J Cell Biochem 98:
440–450.
45. del Rincon SV, Guo Q, Morelli C, Shiu HY, Surmacz E, et al. (2004) Retinoic
acid mediates degradation of IRS-1 by the ubiquitin-proteasome pathway, via a
PKC-dependant mechanism. Oncogene 23: 9269–9279.
46. D’Ambrosio C, Keller SR, Morrione A, Lienhard GE, Baserga R, et al. (1995)
Transforming potential of the insulin receptor substrate 1. Cell Growth Differ 6:
557–562.
47. Tseng YH, Butte AJ, Kokkotou E, Yechoor VK, Taniguchi CM, et al. (2005)
Prediction of preadipocyte differentiation by gene expression reveals role of
insulin receptor substrates and necdin. Nat Cell Biol 7: 601–611.
48. Strange RC, Spiteri MA, Ramachandran S, Fryer AA (2001) Glutathione-S-
transferase family of enzymes. Mutat Res 482: 21–26.
49. Townsend DM, Tew KD (2003) The role of glutathione-S-transferase in anti-
cancer drug resistance. Oncogene 22: 7369–7375.
50. Etcheverry A, Aubry M, de Tayrac M, Vauleon E, Boniface R, et al. (2010)
DNA methylation in glioblastoma: impact on gene expression and clinical
outcome. BMC Genomics 11: 701.
51. Bell A, Bell D, Weber RS, El-Naggar AK (2011) CpG island methylation
profiling in human salivary gland adenoid cystic carcinoma. Cancer 117: 2898–
2909.
52. Kearns PR, Chrzanowska-Lightowlers ZM, Pieters R, Veerman A, Hall AG
(2003) Mu class glutathione S-transferase mRNA isoform expression in acute
lymphoblastic leukaemia. Br J Haematol 120: 80–88.
53. Skubitz K, Skubitz A (2003) Differential gene expression in leiomyosarcoma.
Cancer 98: 1029–1038.
54. Morelli C, Garofalo C, Bartucci M, Surmacz E (2003) Estrogen receptor-alpha
regulates the degradation of insulin receptor substrates 1 and 2 in breast cancer
cells. Oncogene 22: 4007–4016.
55. Sun M, Paciga JE, Feldman RI, Yuan Z, Coppola D, et al. (2001)
Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer,
regulates and is induced by estrogen receptor alpha (ERalpha) via interaction
between ERalpha and PI3K. Cancer Res 61: 5985–5991.
56. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, et al.
(2001) Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen
receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 276:
9817–9824.
Genome-Wide DNA Methylation Analysis in Leiomyomas
PLOS ONE | www.plosone.org 13 June 2013 | Volume 8 | Issue 6 | e66632
